Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1995; 74(01): 090-093DOI: 10.1055/s-0038-1642658 Colloquium Natural Inhibitors of Blood Cogulation Schattauer GmbH Stuttgart Tissue Factor Pathway Inhibitor Autor*innen Institutsangaben George J Broze Jr. Jewish Hospital at Washington University, Division of Hematology and Oncology, Department of Medicine, St. Louis, MO, USA Artikel empfehlen Abstract als PDF herunterladen(opens in new window) Artikel einzeln kaufen(opens in new window) PDF (324 kb) Referenzen References 1 Thomas L. Studies on the intravascular thromboplastin effect of tissue suspensions in mice: II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component Bull Johns Hopkins Hosp 1947; 81: 26-42 2 Schneider CL. The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am J Physiol 1947; 149: 123-129 3 Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9 (27) 1-182 4 Broze Jr GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Nat Acad Sci USA 1987; 84: 1886-1890 5 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDN A coding forthe lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. Journal of Biological Chemistry 1988; 263: 6001-6004 6 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII- tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343 7 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546 8 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393 9 Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thrombosis Research 1987; 46: 527-537 10 Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arteriosclerosis & Thrombosis 1993; 13: 1066-1075 11 Abumiya T, Nakamura S, Takenaka A, Takenaka O, Yoshikuni Y, Miyamoto S, Kimura T, Enjyoji K, Kato H. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb 1994; 14: 483-488 12 Hansen J-B, Huseby N-E, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Arterioscler Thromb 1994; 14: 223-229 13 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. Journal of Biological Chemistry 1989; 264: 18832-7 14 Broze Jr GJ, Lange GW, Duffin KL, MacPhail L. Heterogeneity of Plasma Tissue Factor Pathway Inhibitor. Blood Coag Fibrinol 1994; 5: 551-559 15 Valentine S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C- terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro andin vivo interaction with lipoproteins. Blood Coag Fibrinol 1993; 4: 713-720 16 Novotny WF. Tissue Factor Pathway Inhibitor. Sem Thromb Hemost 1994; 20: 101-108 17 Wam-Cramer BJ, Maki SL. Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma. Thromb Res 1992; 67: 367-383 18 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-2025 19 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thrombosis Research 1988; 50: 803-813 20 Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol 1994; 5: 819-823 21 Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein-as sociated coagulation inhibitor. Blood 1991; 78: 394-400 22 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23: 103-106 23 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein -associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73 24 Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb & Haemos 1993; 69: 366-369 25 Tyson DR, Kuppuswamy MN, Broze Jr GJ, Bajaj SP. Revised DNA sequence of exon 1 and 5’ flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993; 70: 269-273 26 Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CJ, Gimbrone MJ. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element [published erratum appears in Proc Natl Acad Sci USA 1993 90(16):7908]. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 4591-4595 27 Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG, Wun TC. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thrombosis & Haemostasis 1992; 68: 33-36 28 Bregengaard C, Nordfang O, Ostergaard P, Petersen JG L, Meyn G, Diness V, Svendsen O, Hedner U. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457 29 Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994; 63: 601-637 30 Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. Journal of Biological Chemistry 1992; 267: 26172-26180 31 Kounnas MZ, Aig raves WS, Strickland DK. The 39-kDa receptor-as sociated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. Journal of Biological Chemistry 1992; 267: 21162-21166 32 Warshawsky I, Broze Jr GJ, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-6668 33 Warshawsky I, Bu G, Mast A, Saffitz JE, Broze Jr. GJ, Schwartz AL. The Carboxy-terminus of Tissue Factor Pathway Inhibitor is Required for Interacting with Hepatoma Cells In Vitro andIn vivo. Submitted to JClin Invest 1994. 34 Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitorlevels in uremic patients on regularhemodialysis. Thromb Haemost 1994; 71: 275-279 35 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-as sociated coagulation inhibitor. Nature 1989; 338: 518-520 36 Higuchi DA, Wun TC, Likert KM, Broze GJ. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-1719 37 Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-10 38 Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze Jr GJ. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagulation & Fibrinolysis 1993; 4: 661-669 39 Petersen JG, Meyn G, Rasmussen JS, Petersen J, Bjom SE, Jonassen I, Christiansen L, Nordfang O. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae. Journal of Biological Chemistry 1993; 268: 13344-13351 40 Callander NS, Rao LV, Nordfang O, Sandset PM, Warn CB, Rapapoit SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VHa-tissue factor complexes in the absence of factor Xa J BiolChem 1992; 267: 876-882 41 Girard TJ, Broze Jr GJ. Tissue factor pathway inhibitor. In: Methods in Enzymology. Lorand L, and Mann KG. ed. Academic Press; Orlando; 1993: 196-209 42 Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard PB, Petersen JG, Nielsen G, Hedner U. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI 1 -161) in experimental venous thrombosis— a comparison with low molecular weightheparin. Thrombosis & Haemostasis 1994; 71: 214-219 43 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze Jr GJ, Warren TG, Wun TC. Recombinant lipoprotein- associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-1545 44 Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin- induced disseminated intravascular coagulation in rabbits. Blood Coagulation & Fibrinolysis 1993; 4: 699-706 45 Creasey AA, Chang AC, Feigen L, Wun TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J din Invest 1993; 91: 2850-2856 46 Khouri RK, Koudsi B, Raiding F, Omberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Annals of Plastic Surgery 1993; 30: 398-402 discussion 402-4 47 Oltrana L, Speidel CM, Recchia D, Abendschein DR. Inhibition of tissue factor-mediated thrombosis markedly attenuates stenosis after balloon- induced arterial injury in hyperlipidemic minipigs. Circulation 1994; 90: 1-344 48 McGee MP, Li LC. Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages J Biol Chem 1991; 266: 8079-8085 49 Erhardtsen E, Mads T, Madsen T, Mirella E, Hedner U, Diness V, Glazer S, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced hemophilia A. Thromb Haemost 1993; 69: 556-556 50 Girard TJ, Gailani D, Broze Jr GJ. Complementary DNA sequencing of canine tissue factor path way inhibitor reveals a unique nanomeric repetitive sequence between the second and third Kunitz domains. Biochem J 1994; 303: 923-928
